3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
9
Terminated
2
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
3
Sarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lymphoma, Large B-Cell, Diffuse
2
Recurrence
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Hodgkin Disease
1
Disease Progression
1
Interventions
Cyclophosphamide
5
Cytarabine
4
Peripheral Blood Stem Cell Transplantation
3
Etoposide
3
fludarabine phosphate
2
denileukin diftitox
2
brigatinib
2
Vincristine
2
Rituximab
2
Radiotherapy
2
Prednisone
2
Pentetic Acid
2
Methotrexate
2
Doxorubicin
2
Brentuximab Vedotin
2
sargramostim
1
sapanisertib
1
iratumumab
1
ibritumomab tiuxetan
1
ethanolamine oleate
1
ceritinib
1
Whole-Body Irradiation
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Trimethoprim
1
Triamcinolone Acetonide
1
Transplantation
1
Thiotepa
1
Tacrolimus
1
Sulfamethoxazole
1
Sodium Chloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Lymphoma, Large-Cell, Anaplastic
×
Ifosfamide
×
Clear all
NCT00801918
2013-05-15
Denileukine Diftitox for Relapsed ALCL
Columbia University
Phase 2
Withdrawn